PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY
申请人:Smaill Jeffrey Bruce
公开号:US20120077811A1
公开(公告)日:2012-03-29
The invention provides novel prodrug compounds comprising a kinase inhibitor and a reductively-activated fragmenting aromatic nitroheterocycle or aromatic nitrocarbocycle trigger, where the compound carries a positive charge. In preferred embodiments, the compounds are of Formula I:
where: X is any negatively charged counterion; R
1
is a group of the formula —(CH
2
)
n
Tr, where Tr is an aromatic nitroheterocycle or aromatic nitrocarbocycle and —(CH
2
)
n
Tr acts as a reductively-activated fragmenting trigger; and n is an integer from 0 to 6; R
2
, R
3
and R
4
may each independently be selected from aliphatic or aromatic groups of a tertiary amine kinase inhibitor (R
2
)(R
3
)(R
4
)N, or two of R
2
, R
3
, and R
4
may form an aliphatic or aromatic heterocyclic amine ring of a kinase inhibitor, or one of R
2
, R
3
and R
4
may be absent and two of R
2
, R
3
and R
4
form an aromatic heterocyclic amine ring of a kinase inhibitor.
The compounds of the invention are useful in treating proliferative diseases such as cancer.
Prodrug forms of kinase inhibitors and their use in therapy
申请人:Smaill Jeffrey Bruce
公开号:US09073916B2
公开(公告)日:2015-07-07
The invention provides novel prodrug compounds comprising a kinase inhibitor and a reductively-activated fragmenting aromatic nitroheterocycle or aromatic nitrocarbocycle trigger, where the compound carries a positive charge. In preferred embodiments, the compounds are of Formula I:
where: X is any negatively charged counterion; R1 is a group of the formula —(CH2)nTr, where Tr is an aromatic nitroheterocycle or aromatic nitrocarbocycle and —(CH2)nTr acts as a reductively-activated fragmenting trigger; and n is an integer from 0 to 6; R2, R3 and R4 may each independently be selected from aliphatic or aromatic groups of a tertiary amine kinase inhibitor (R2)(R3)(R4)N, or two of R2, R3, and R4 may form an aliphatic or aromatic heterocyclic amine ring of a kinase inhibitor, or one of R2, R3 and R4 may be absent and two of R2, R3 and R4 form an aromatic heterocyclic amine ring of a kinase inhibitor.
The compounds of the invention are useful in treating proliferative diseases such as cancer.
[EN] PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY<br/>[FR] FORMES PROMÉDICAMENTS D'INHIBITEURS DE KINASE ET LEUR UTILISATION EN THÉRAPIE